The latest price target for Nemaura Medical (OTCEM:NMRD) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $2.50 expecting NMRD to rise to within 12 months (a possible 249999900.00% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Nemaura Medical (OTCEM:NMRD) was provided by HC Wainwright & Co., and Nemaura Medical maintained their buy rating.

There is no last upgrade for Nemaura Medical

There is no last downgrade for Nemaura Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nemaura Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nemaura Medical was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.

While ratings are subjective and will change, the latest Nemaura Medical (NMRD) rating was a maintained with a price target of $7.00 to $2.50. The current price Nemaura Medical (NMRD) is trading at is $0.00, which is out of the analyst’s predicted range.